2026-07-21T11:34:08Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/231062024-11-29T23:14:28Zcom_20.500.12105_2173com_20.500.12105_2051col_20.500.12105_19597

00925njm 22002777a 4500 dc Ocio, Enrique M author Bringhen, Sara author Martinez-Lopez, Joaquin author San-Miguel, Jesus author Oliva, Stefania author Rodriguez-Otero, Paula author Le Roux, Nadia author Dong, Yvonne author Doroumian, Severine author Macé Sandrine author Mateos, Maria-Victoria author 2023-02 Hemasphere . 2023 ;7(2):e829. 10.1097/HS9.0000000000000829 2572-9241 HemaSphere 36751513 https://hdl.handle.net/20.500.12105/23106 Phase 1b Study of Isatuximab in Combination With Bortezomib, Cyclophosphamide, and Dexamethasone in Newly Diagnosed, Transplant-ineligible Multiple Myeloma Patients.